Brief Abatacept Therapy Delays Rheumatoid Arthritis Onset for Years
A long-term analysis from King’s College London shows that a 12-month course of abatacept in people at high risk of rheumatoid arthritis can delay disease onset by up to four years, with benefits persisting after treatment ends; strongest effects were in those at highest risk identified by specific autoantibodies, and while the therapy does not permanently prevent RA, early immune modulation may lessen future symptom burden and support preventive strategies, with safety comparable to placebo.
